Ultima Genomics, a pioneer in ultra-high throughput sequencing technology, announced that its UG 100™ sequencing platform has been chosen to support the Regeneron Genetics Center® (RGC™) in a new large-scale proteomics initiative in the United States. The study will analyze 200,000 blood serum samples collected through RGC’s long-standing collaboration with Geisinger Health System.
This U.S. effort will complement the UK Biobank Pharma Proteomics Project—currently the world’s largest proteomics study—which will use the UG 100 platform to analyze 600,000 samples from UK Biobank participants. Together, these two studies underscore the increasing adoption of cost-effective, high-throughput sequencing solutions for large-scale proteomic and multi-omics research.
Both initiatives will integrate the Olink Explore HT platform with Ultima’s UG 100 system, chosen for its exceptional scalability, operational efficiency, and suitability for population-scale data generation.
“We are proud to contribute to the advancement of large-scale proteomics research, which holds tremendous promise for driving scientific and clinical breakthroughs,” said Gilad Almogy, founder and CEO of Ultima Genomics. “These collaborative studies with RGC reflect the growing momentum around population-wide proteomic analyses enabled by Ultima’s platform.”